Please login to the form below

Not currently logged in
Email:
Password:

Former Glaxo CEO Ernest Mario to chair Chimerix

Pharma veteran has previously also served as CEO of Alza and Reliant

Chimerix Ernest MarioChimerix has appointed pharma veteran and former CEO of Glaxo Holdings Dr Ernest Mario as the company's new chairman.

Mario (pictured right) was CEO of Glaxo from 1989 to 1993, ahead of its subsequent merger with Wellcome in 1995 and then SmithKline Beecham in 2000 to eventually form GlaxoSmithKline (GSK).

Following his departure from Glaxo, Dr Mario served as chairman and CEO of Alza from 1993 until its acquisition by Johnson & Johnson (J&J) in 2011.

He then held the role of chairman and CEO of Reliant Pharmaceutical from 2003 until its acquisition by GSK in 2007.

Dr Mario currently serves as chairman and CEO of US-based biopharma Capnia.

"Ernie brings to Chimerix a unique breadth and depth of experiences across large and early stage pharmaceutical firms,” said Kenneth Moch, president and CEO of Chimerix.

“His knowledge will be invaluable as we seek to progress our lead compound, CMX001, through phase III clinical development and commercial launch."

Dr Mario replaces Dr James Niedel, who will remain as a member of the board at Chimerix.

26th February 2013

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics